Bisantrene

• CAT Number: I004873
• CAS Number: 78186-34-2
• Molecular Formula: C22H22N8
• Molecular Weight: 398.46
• Purity: ≥95%
• Target: Topoisomerase
• Solubility: DMSO
• Storage: Room Temperature
• IUPAC Name: N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine
• InChI: InChI=1S/C22H22N8/c1-2-6-16-15(5-1)19(13-27-29-21-23-9-10-24-21)17-7-3-4-8-18(17)20(16)14-28-30-22-25-11-12-26-22/h1-8,13-14H,9-12H2,(H2,23,24,29)(H2,25,26,30)/b27-13+,28-14+
• InChIKey: NJSMWLQOCQIOPE-OCHFTUDZSA-N
• SMILES: C1CN=C(N1)NN=CC2=C3C=CC=CC3=C(C4=CC=CC=C42)C=NNC5=NCCN5

Bisantrene（Cat No.:I004873） is a potent antitumor drug that belongs to the class of eukaryotic type II topoisomerase inhibitors. It exerts its therapeutic effects by targeting and inhibiting the activity of topoisomerase enzymes, specifically type II topoisomerases. These enzymes are involved in the regulation of DNA topology and are essential for DNA replication, transcription, and recombination. By inhibiting topoisomerase activity, bisantrene disrupts DNA processes and induces DNA damage, ultimately leading to the suppression of tumor cell growth and proliferation.

Reference

[1]. Sissi C, et al. DNA-binding preferences of Bisantrene analogues: relevance to the sequence specificity of drug-mediated topoisomerase II poisoning. Mol Pharmacol. 1998 Dec;54(6):1036-45.
[2]. Yap HY, et al. Bisantrene, an active new drug in the treatment of metastatic breast cancer. Cancer Res. 1983 Mar;43(3):1402-4.